Specialized ATMP Focus Recipharm Advanced Bio’s commitment to developing and manufacturing advanced therapy medicinal products positions it as an ideal partner for biotech and pharma companies seeking specialized CDMO services in live viruses, viral vectors, and nucleic acid-based therapies.

Strategic Collaborations Recent partnerships with renowned institutions like the University of Oxford and companies such as Hongene Biotech and NewBiologix demonstrate Recipharm’s expanding capacity and expertise in blood-stage vaccines, sgRNA manufacturing, and biologics, opening doors for collaborative projects.

Innovative Technology The development of next-generation Process Analytical Technologies and scalable cell-free protein expression platforms shows Recipharm’s focus on cutting-edge manufacturing solutions, which can attract clients seeking advanced, real-time analytics and efficient bioprocessing.

Growing Market Presence With revenue estimates between 50 to 100 million dollars and active engagement in high-profile industry events, Recipharm is well-positioned to attract expansion-minded biotech firms aiming to leverage its specialized capabilities for rapid development.

Targeted Service Expansion Recipharm's expansion into sgRNA manufacturing and viral vector licensing highlights its ability to meet emerging client demands in gene therapy, offering sales opportunities with innovative biologics companies seeking comprehensive manufacturing solutions.